Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures

European Neurology

Volumn 48, Issue 4, 2002, Pages 200-203

  Benetello, Pierpaola ^a   Furlanut, Marco ^a   Baraldo, Massimo ^b   Tonon, Agnese ^a   Furlanut, Mario ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Lamotrigine; Resistant partial seizures; Serum levels

Indexed keywords

CARBAMAZEPINE; EPOXIDE; LAMOTRIGINE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; FEMALE; FOCAL EPILEPSY; HUMAN; ILLUSION; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; RESISTANT PARTIAL SEIZURE; SIDE EFFECT; TREATMENT RESPONSE; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; DRUG RESISTANCE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 0036045221     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066165     Document Type: Article

References (23)

1. Kilpatrick ES, Forrest G,Brodie MJ: Concentration-effect and concentration-toxicity relations with lamotrigine: A prospective study. Epilepsia 1996;37:534-538.
2. Tomson T, Johannessen SI: Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000:55:697-705.
3. Rambeck B, Specht IJ, Wolf P: Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996;31:309-324.
4. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC: Lamotrigine and therapeutic drug monitoring: Retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998;46:547-551.
5. Warner T, Patsalas PN, Prevett M: Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-150.
6. Wolf P: Lamotrigine: Preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-79.
7. Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B: Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-187
8. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
9. Lensmeyer GL, Gidal BE, Wiebe DA: Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Ther Drug Monit 1997;19:292-300.
10. Pisani F, Di Perri R, Perucca E, Richens A: Interaction of lamotrigine with sodium valproate. Lancet 1993;341:1224.
11. Yuen AWC, Land G, Weatherley BC, Peck AW: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-513.
12. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A: The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-1146.
13. Bottiger Y, Svenson JO, Stahle L: Lamotrigine drug interactions in a TDM material. Ther Drug Monit 1999;21:171-174.
14. Lees G, Leach MJ: Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993;28:190-199.
15. Fariello RG, Varasi M, Smith MC: Valproic Acid: Mechanism of action: in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs. ed 4. New York. Raven Press. 1995, pp 581-588.
16. Richens A: Safety of lamotrigine. Epilepsia 1994;35(suppl 5):S37-S40.
17. Pisani F, Xiao B, Fazio A, Spina E, Perucca E, Tomson T: Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994;19:245-248.
18. Eriksson AS, Hoppu K, Nergardh A, Borcus L: Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy Epilepsia 1996;37:769-71
19. Gidal BE, Rutecki P, Shaw R, Maly MM, Collins DM, Pitterle ME: Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res 1997;28:207-211.
20. Benedetti MS: Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies. Fundam Clin Pharmacol 2000;14:301-319.
21. Rambeck B, Salke-Treumann A, May T, Bocnigk HE: Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. Eur Neurol 1990;30:79-83.
22. Theodore WH, Narang PK, Holmes MD, Reeves P, Nice FJ: Carbamazepine and its epoxide: Relation of plasma levels to toxicity and seizure control. Ann Neurol 1989;25:194-196.
23. Browne TR, Penry JK: Benzodiazepines in the treatment of epilepsy. Epilepsy 1973;14:277-310.